CN100358536C - Prepn process and formula of compound chondroitin sulfate tablet - Google Patents
Prepn process and formula of compound chondroitin sulfate tablet Download PDFInfo
- Publication number
- CN100358536C CN100358536C CNB031196454A CN03119645A CN100358536C CN 100358536 C CN100358536 C CN 100358536C CN B031196454 A CNB031196454 A CN B031196454A CN 03119645 A CN03119645 A CN 03119645A CN 100358536 C CN100358536 C CN 100358536C
- Authority
- CN
- China
- Prior art keywords
- chondroitin sulfate
- osteocomma
- formula
- chrondroitin
- strong
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229920001287 Chondroitin sulfate Polymers 0.000 title claims abstract description 18
- 229940059329 chondroitin sulfate Drugs 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title abstract description 4
- 230000008569 process Effects 0.000 title abstract description 3
- -1 compound chondroitin sulfate Chemical class 0.000 title abstract 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 15
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims abstract description 13
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000008696 isoflavones Nutrition 0.000 claims abstract description 13
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 claims abstract description 11
- 244000068988 Glycine max Species 0.000 claims abstract description 11
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 11
- 229960001911 glucosamine hydrochloride Drugs 0.000 claims abstract description 11
- 239000002671 adjuvant Substances 0.000 claims abstract description 10
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 15
- 239000002131 composite material Substances 0.000 claims description 15
- 239000002994 raw material Substances 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 239000000741 silica gel Substances 0.000 claims description 6
- 229910002027 silica gel Inorganic materials 0.000 claims description 6
- 210000000988 bone and bone Anatomy 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract 2
- 206010057178 Osteoarthropathies Diseases 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 235000013402 health food Nutrition 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000009748 deglutition Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 210000000537 nasal bone Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Abstract
The present invention relates to health-care food having the functions of prevention and adjuvant auxiliary for osteoarthropathy, particularly to a technological formula of a compound chondroitin sulfate bone strengthening tablet. The formula comprises 30 to 50 wt% of chondroitin sulfate, 40 to 60 wt% of glucosamine hydrochloride, 2 to 3 wt% of soybean isoflavone and auxiliary materials as the rest. The compound chondroitin sulfate bone strengthening tablet prepared according to the process formula of the present invention integrates the therapeutical effects of the chondroitin sulfate and the prevention effects of the soybean isoflavone and is the best health-care food with the characteristics of quick disintegration, good dissolution, convenient administration, benefit to absorption, etc.
Description
Technical field:
The present invention relates to osteoarthritis is had the health food of prevention and auxiliary treatment, particularly a kind of sulfate composite chrondroitin is good for osteocomma.
Background technology:
Rheumatic arthritis, osteoarthritis and osteoporosis have become the commonly encountered diseases of middle-aged and elderly people, and among the crowd more than 40 years old, such disease sickness rate is up to 74%.At present the common medicine of this class disease of treatment has analgesics, NSAID (non-steroidal anti-inflammatory drug), local hormone injection and intra-articular injection hyaluronidase etc., and these medicines generally can only relief of symptoms, is difficult to thoroughly improve the function of joint and the state of an illness.Though many studies show that, the merging of chondroitin sulfate and glucosamine hydrochloride are at the application of osteoarthritis, the improvement rate of its clinical symptoms can reach 50～80%, the sustainable some months of good result after the drug withdrawal; The particularly absorption of Semen sojae atricolor and bean product in the meals of dietary factors, preventive effect that can be certain to having of such disease.But, bibliographical information is not arranged at present as yet, above-mentioned two aspect achievements in research can be combined and develop and have the health care and the active drug or the health food of auxiliary treatment function.
Summary of the invention:
The purpose of this invention is to provide the preventive effect of a kind of therapeutical effect that integrates chondroitin sulfate and soybean isoflavone, the strong osteocomma of sulfate composite chrondroitin with health food function.
The technical scheme that realizes the foregoing invention purpose is: its raw material constitutes (weight %): chondroitin sulfate 30～50, and glucosamine hydrochloride 40～60, soybean isoflavone 2～3, surplus is an adjuvant.
The technical scheme that realizes the foregoing invention purpose can also be: its raw material constitutes (weight %): chondroitin sulfate 40, glucosamine hydrochloride 50, soybean isoflavone 2.5, adjuvant 7.5.Adjuvant is made up of microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, micropowder silica gel.Its best proportioning (weight %) is: microcrystalline Cellulose 5, low-substituted hydroxypropyl cellulose 1.67, micropowder silica gel 0.83 are formed.
Raw material is formed foundation:
Chondroitin sulfate (Chondroitin Sulfate is hereinafter to be referred as CS) is the animal mucopolysaccharide that extracts by in the cartilaginous tissues such as animal larynx bone, nasal cartilages, trachea, bone tendon, ligament.Being distributed widely in the tissue of humans and animals, is the ingredient of conjunctive tissues such as the cartilage that constitutes animal, tendon, blood vessel wall, skin, and main component is mixture of isomers such as CSA, CSC, sulphuric acid angle (skin) quality, hyaluronic acid and a small amount of CSB.CS plays an important role in tissue growth and regeneration and on the immune function of body and many sources of infection (antibacterial, virus).The D-glucosamine hydrochlorate is called for short glucosamine hydrochloride, and (D-Glucosamine Hydrochloride GAH), is a kind of marine biological preparation, has the important physical meaning in human body.CS sodium salt and D-glucosamine salt hydrochlorate and D-galactose therapeutic alliance arthritis, but mitigation symptoms, its mechanism can be removed sodium ion in a large amount of absorption synovial membranes for CS, promotes bone matrix hyperplasia, and destructive cartilage is recovered normally.Osteoporosis is formed by the loss of calcium, bone amount, collagen protein, and the mixture of chondroitin sulfate, glucosamine hydrochloride is synthetic in catalysis collagen and proteoglycan, thereby repairs cartilage and treatment of arthritis.
Isoflavone is a class phytoestrogen that mainly is present in Semen sojae atricolor and the bean product.In recent years, a large amount of cell culture, tissue culture and zoopery show that isoflavone can produce obviously influence to bone metabolism, promotes bone formation, suppresses bone resorption, effectively prevents osteoporotic generation.
Sulfate composite chrondroitin of the present invention is good for osteocomma, be that the above achievement in research is a foundation, through a large amount of test, prescription, dosage form and corresponding technology etc. are explored, thereby determined raw material form in the proportioning of chondroitin sulfate and glucosamine hydrochloride and adjuvant.Compare with external similar technology, dosed soybean isoflavone composition as Chinese medicine extract, determined its optimal proportion in prescription, select and determined proper supplementary material and charge ratio, adopted the deglutition type tablet, preferably resolve formed product, shorten problem such as disintegration of tablet time, have that disintegrate is fast, stripping good, taking convenience, help characteristics such as absorption.Therefore, according to the strong osteocomma of the said sulfate composite chrondroitin of the present invention, be the best health food that integrates the preventive effect of the therapeutical effect of chondroitin sulfate and soybean isoflavone.
On August 20th, 2002, Chinese Academy Of Preventive Medicine Research Institute Of Nutrition And Food Hygiene health food functional check center is checked the strong osteocomma of sulfate composite chrondroitin of the present invention, the result is as follows: per os gives the strong osteocomma of sulfate composite chrondroitin of rat various dose, experimental result shows, it is low to be good for osteocomma, in, high dose group rat femur weight in wet base, dry weight, bone density (BMD), bone mineral content (BMC) and calcium content of bone and model control group significantly increase, all there were significant differences (P＜0.05), according to criterion in " the health food function assessment assessment process and the method for inspection " exposure draft, think that the strong osteocomma of sulfate composite chrondroitin of the present invention increases the effect of rat bone density.
On August 12nd, 2002, health inspection center in Hebei province's has carried out the toxicity check to the strong osteocomma of sulfate composite chrondroitin of the present invention, and the result is: this strong osteocomma is to the LD of the large and small Mus of two kinds of sexes
50All, illustrate that this strong osteocomma belongs to non-poisonous material greater than 21500mg/kg.bw; Three mutagenicity tests are feminine gender as a result; 30 days every indexs of feeding trial of rat are all no abnormal.
The specific embodiment:
Below in conjunction with embodiment in detail the present invention is described in detail.Raw material by the strong osteocomma of sulfate composite chrondroitin of the present invention constitutes, and can have and give three specific embodiments in the following table.
| Material name | Embodiment 1 | Embodiment 2 | Embodiment 3 | ||||
| Weight % | Weight g | Weight % | Weight g | Weight % | Weight g | ||
| Chondroitin sulfate | 30 | 900 | 40 | 1200 | 50 | 1500 | |
| Glucosamine hydrochloride | 60 | 1800 | 50 | 1500 | 40 | 1200 | |
| Soybean isoflavone | 2 | 60 | 2.5 | 75 | 3 | 90 | |
| Adjuvant | Microcrystalline Cellulose | 5 | 150 | 5 | 150 | 5 | 150 |
| Low-substituted hydroxypropyl cellulose | 2 | 60 | 1.67 | 50 | 1.33 | 40 | |
| Micropowder silica gel | 1 | 30 | 0.83 | 25 | 0.67 | 20 | |
| Add up to | 100 | 3000 | 100 | 3000 | 100 | 3000 | |
Total raw material that each embodiment gets is 3000g in the table, can make 6000 of the strong osteocomma agent of sulfate composite chrondroitin by following preparation technology.
Preparation technology:
1, gets material respectively by the formula ratio of the chondroitin sulfate of giving, glucosamine hydrochloride, soybean isoflavone, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose in the last table, with each raw material mix homogeneously.
2, be wetting agent system soft material with 95% ethanol, 20 order nylon wires are granulated.
3,60 ℃ of oven dryings are about 1 hour.
4,20 order stainless (steel) wire granulate.
5, the formula ratio by the micropowder silica gel of giving in the last table weighs this raw material, with dried granule mix homogeneously.
6, chemical examination granule content determines that sheet is heavy.
7, with diameter 12mm drift tabletting, control disintegration, hardness before the tabletting.
8, after the assay was approved, packing.
9, send radiation center sterilization (cobalt 60 irradiation, dosage 3kgy).
10, by the check of company standard draw samples, warehousing after passing.
Claims (4)
1, the strong osteocomma of a kind of sulfate composite chrondroitin is characterized in that its raw material constitutes (weight %): chondroitin sulfate 30～50, and glucosamine hydrochloride 40～60, soybean isoflavone 2～3, surplus is an adjuvant.
2, the strong osteocomma of sulfate composite chrondroitin according to claim 1 is characterized in that its raw material constitutes (weight %): chondroitin sulfate 40, glucosamine hydrochloride 50, soybean isoflavone 2.5, adjuvant 7.5.
3, the strong osteocomma of sulfate composite chrondroitin according to claim 1 and 2 is characterized in that adjuvant is made up of microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, micropowder silica gel.
4, the strong osteocomma of sulfate composite chrondroitin according to claim 1 and 2 is characterized in that adjuvant is made up of (weight %) microcrystalline Cellulose 5, low-substituted hydroxypropyl cellulose 1.67, micropowder silica gel 0.83.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031196454A CN100358536C (en) | 2003-03-19 | 2003-03-19 | Prepn process and formula of compound chondroitin sulfate tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031196454A CN100358536C (en) | 2003-03-19 | 2003-03-19 | Prepn process and formula of compound chondroitin sulfate tablet |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1531932A CN1531932A (en) | 2004-09-29 |
| CN100358536C true CN100358536C (en) | 2008-01-02 |
Family
ID=34285193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031196454A Expired - Lifetime CN100358536C (en) | 2003-03-19 | 2003-03-19 | Prepn process and formula of compound chondroitin sulfate tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100358536C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101156630B (en) * | 2007-11-16 | 2011-05-18 | 中国农业大学 | Bone joint reinforcing milk |
| CN103461674B (en) * | 2013-09-23 | 2014-12-31 | 大连圣弘医药有限公司 | Formula of pet functional food capable of effectively activating pet joints and preparation method of food |
| CN104757365A (en) * | 2014-01-03 | 2015-07-08 | 周颖 | Composite chondroitin sulfate and red yeast rice tablet |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1364464A (en) * | 2002-01-29 | 2002-08-21 | 郑刚 | Aminoglucose hydrochloride medicinal composition |
-
2003
- 2003-03-19 CN CNB031196454A patent/CN100358536C/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1364464A (en) * | 2002-01-29 | 2002-08-21 | 郑刚 | Aminoglucose hydrochloride medicinal composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1531932A (en) | 2004-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Deal et al. | Nutraceuticals as therapeutic agents in osteoarthritis: the role of glucosamine, chondroitin sulfate, and collagen hydrolysate | |
| CN102224896B (en) | Health food for enhancing human immunity and increasing bone mineral density and preparation method thereof | |
| CN101181294A (en) | Pharmaceutical composition for curing osteoarthritis | |
| CN102949710B (en) | Pharmaceutical composition or healthcare product for increasing bone mineral density and preparation method of pharmaceutical composition or healthcare product | |
| CN105920031A (en) | Composition for joint repair and preparation method of composition | |
| CN111467481A (en) | Composition for improving and/or preventing osteoarthritis and application thereof | |
| CN101450055A (en) | Soluble powder for treating livestock and poultry bacterial infection and parasitic disease | |
| CN100358536C (en) | Prepn process and formula of compound chondroitin sulfate tablet | |
| CN102441023B (en) | Injection composition for treating orthopedic diseases | |
| US20230250199A1 (en) | Low molecular weight chondroitin sulfate, composition, preparation method and use thereof | |
| CN100488514C (en) | Slowly released solid ivermectin microballoon preparation | |
| CN105770850A (en) | Health care product for adjuvant treatment of osteoarticular diseases and preparation method of health care product | |
| CN109464651A (en) | A kind of amelioration of disease induced by metabolic disorder in cartilage healthy food and composite medicine | |
| CN101549177B (en) | Medicament coating applied to fixation screw in rachis, preparation method thereof and application thereof | |
| CN103238839A (en) | Food composition containing collagen used for maintaining joints | |
| CN110169965B (en) | Application of compound in treating cartilage degenerative disease | |
| WO2018107324A1 (en) | Calcium supplement composition for decreasing risk of hypercalcemia and use thereof | |
| CN105267949A (en) | Medicine prescription for degenerative arthritis and osteoporosis and tablet preparation method thereof | |
| Wei et al. | Artificial tiger bone powder for improving the quality of life in elderly patients with fracture | |
| CN1044860C (en) | Rheumatism medicine | |
| ES2325392B1 (en) | COMPOSITION FOR THE TREATMENT OF ARTROSIS. | |
| CN110507602A (en) | A kind of gelling agent of Glucosamine and preparation method thereof | |
| WO2021179319A1 (en) | Composition containing hydrolyzed chondroitin sulfate for preventing and treating osteoarthropathy | |
| CN113712990A (en) | Composition and preparation method and application thereof | |
| CN101690728B (en) | Composition for treating osteoarthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: TANGSHAN SANXIN BIOCHEMICAL PRODUCTS CO., LTD. Free format text: FORMER OWNER: ZHOU YING Effective date: 20110513 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 063010 NO. 5, UNIT 4, BUILDING 126, DONGGONGFANG, LINXI, GUYE DISTRICT, TANGSHAN CITY, HEBEI PROVINCE TO: 063100 SOUTH OF XILIJIATAO VILLAGE, HUANGTUO, GUYE DISTRICT, TANGSHAN CITY, HEBEI PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110513 Address after: 063100, Hebei, Guye province Tangshan City District Huang Tuo West Li Jia Village South Patentee after: Tangshan three Xin biochemical products Co.,Ltd. Address before: 063010 Hebei province Tangshan City Linxi East Guye District 126 building 4 unit 5 Room Patentee before: Zhou Ying |
|
| ASS | Succession or assignment of patent right |
Owner name: TANGSHAN FULE PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: TANGSHAN SANXIN BIOCHEMICAL PRODUCTS CO., LTD. Effective date: 20140102 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 063100 TANGSHAN, HEBEI PROVINCE TO: 063000 TANGSHAN, HEBEI PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140102 Address after: 063000 three Xin hi tech Industrial Park, Guye District, Hebei, Tangshan City Patentee after: Tangshan Fule Pharmaceutical Co.,Ltd. Address before: 063100, Hebei, Guye province Tangshan City District Huang Tuo West Li Jia Village South Patentee before: Tangshan three Xin biochemical products Co.,Ltd. |
|
| PP01 | Preservation of patent right |
Effective date of registration: 20160415 Granted publication date: 20080102 |
|
| RINS | Preservation of patent right or utility model and its discharge | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20170415 Granted publication date: 20080102 |
|
| PD01 | Discharge of preservation of patent | ||
| PP01 | Preservation of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20170415 Granted publication date: 20080102 |
|
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20211015 Granted publication date: 20080102 |
|
| PD01 | Discharge of preservation of patent | ||
| PP01 | Preservation of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20211015 Granted publication date: 20080102 |
|
| CI03 | Correction of invention patent |
Correction item: preservation of patent right Correct: Revoke the announcement False: Effective date of registration: October 15, 2021 Number: 50-01 Volume: 37 |
|
| CI03 | Correction of invention patent | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20211015 Granted publication date: 20080102 |
|
| PP01 | Preservation of patent right | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20220415 Granted publication date: 20080102 |
|
| PD01 | Discharge of preservation of patent | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20220507 Granted publication date: 20080102 |
|
| PP01 | Preservation of patent right | ||
| PD01 | Discharge of preservation of patent | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20230319 Granted publication date: 20080102 |